Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Chemotherapeutic Approach Will Selectively Starve Cancer Cells

By BiotechDaily International staff writers
Posted on 21 Jul 2013
Blocking the activity of the enzyme eukaryotic elongation factor 2 kinase (eEF2K), which is found in cancer cells but not in normal cells, prevents tumors from adapting to nutrient deprivation and may represent a new chemotherapeutic approach.

The eEF2K enzyme is an essential factor for protein synthesis. It promotes the GTP-dependent translocation of the growing protein chain from the A-site to the P-site of the ribosome. This protein is completely inactivated by EF2 kinase phosphorylation.

EEF2K, which is activated by AMP-kinase (AMPK), has been shown to confer cell survival under acute nutrient depletion by blocking translation elongation. It is expressed in a number of tissues, including the liver, brain, and skeletal muscle. The net effect of AMPK activation is stimulation of hepatic fatty acid oxidation and ketogenesis, inhibition of cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibition of adipocyte lipolysis and lipogenesis, stimulation of skeletal muscle fatty acid oxidation and muscle glucose uptake, and modulation of insulin secretion by pancreatic beta cells.

Investigators at the University of Southampton (United Kingdom) reported in the May 23, 2013, issue of the journal Cell that tumor cells exploit the AMPK-eEF2K pathway to adapt to nutrient deprivation. Adaptation of cancer cells to nutrient withdrawal was found to be severely compromised in cells lacking eEF2K. Moreover, eEF2K knockdown restored sensitivity to acute nutrient deprivation in highly resistant human tumor cell lines. In vivo, overexpression of eEF2K rendered murine tumors remarkably resistant to caloric restriction. Expression of eEF2K strongly correlated with overall survival in human medulloblastoma and glioblastoma multiforme.

Contributing author Dr. Christopher G. Proud, professor of biological sciences at the University of Southampton said, "Cancer cells grow and divide much more rapidly than normal cells, meaning they have a much higher demand for and are often starved of, nutrients and oxygen. We have discovered that a cellular component, eEF2K, plays a critical role in allowing cancer cells to survive nutrient starvation, whilst normal, healthy cells do not usually require eEF2K in order to survive. Therefore, by blocking the function of eEF2K, we should be able to kill cancer cells, without harming normal, healthy cells in the process."

"Protein synthesis – the creation of proteins within cells –is a fundamental process that enables cells to grow, divide, and function," said Dr. Proud. "If it goes wrong, it can contribute to the development of cancer. We are interested in how defects in this process can cause cancers and other diseases."

Related Links:

University of Southampton



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.